Healthy Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Single/ Multiple Dose Study to Assess the Safety , Tolerability, Pharmacokinetics of Mianhuahua Flavonoids Tablets After Oral Administration In Healthy Adult Subjects
The purpose of this study is to determine the safety and tolerability, and to evaluate the pharmacokinetic characteristics of Mianhuahua Flavonoids Tablets after oral administration in healthy adult subjects.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | November 2016 |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Male or female, between 18 and 45 years of age, Body Mass Index (BMI) between 19~24 kg/m2, Weight > or = 50kg - In good health as judged by the investigator - Agreed to take effective contraceptive measures during the test and within 6 months after the last drug administration - Signed informed consent form and fully understood the contents, process and possible adverse reactions of the test Exclusion Criteria: - Pregnancy and lactation - History of kinds of food or drug allergy, or suffering from allergic diseases or allergic constitution - Presence (in screening stage) or history of the acute/chronic organic diseases or clinical manifestations: Including but not limited to blood system, renal disease, liver disease, endocrine system, respiratory system, digestive system, cardiovascular system, nervous system, mental disease, or any disease and physiological conditions interfering with the results of the test - with a clinically significant abnormality in routine serological detection: including Hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infected - History of abuse of drugs, or the result of drug abuse test is positive - Alcohol intake more than 2 units (1 unit is equal to 12 ounces or 360 ml beer, 5 ounces or 150 ml liquor, 1.5 ounces or 45 ml distilled spirits ) per day on average within 3 months before the test, or the result of alcohol test is positive - Smoking more than 5 cigarettes per day, or using quite amount of nicotine products within 3 months before the test, or unable to stop smoking during the test - Excessive consumption of xanthine soda drinks, more than four cups or bottles per day - With major surgical operations and blood or blood component transfusion within 4 weeks before the test - Severe blood loss or blood donation more than 400ml within 2 months before the test - Participation in other drug trials within 3 months before the test - Usage of any drugs within 2 weeks before the test, or within 5 times of drug eliminated half-life or pharmacodynamics half-life; Vaccination within 4 weeks before the test; Acceptance of biological agents within 4 months before the test - Be otherwise unsuitable for the study, in the opinion of the Investigator. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Xinjiang Uygur Pharmaceutical Co., Ltd. | Chinese Academy of Sciences |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability of single and repeated oral administration of Mianhuahua Flavonoids Tablets as measured by the frequency of drug-related clinical adverse events in healthy adults. | Safety and tolerability will be evaluated through Composite Metrics:adverse events, vital signs, electrocardiograms, physical exams, and clinical laboratory assessments. | Period I: single dose,up to 7 Days;Period II: repeated dose,up to 36 Days | Yes |
Secondary | Cmax of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults. | up to 24h | No | |
Secondary | Tmax of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults. | up to 24h | No | |
Secondary | area under curve(AUC) of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults. | up to 24h | No | |
Secondary | t1/2 of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults. | up to 24h | No | |
Secondary | Vd of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults. | up to 24h | No | |
Secondary | Cls of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults. | up to 24h | No | |
Secondary | Css_max of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults. | up to 29 days | No | |
Secondary | Css_min of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults. | up to 29 days | No | |
Secondary | Tss_max of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults. | up to 29 days | No | |
Secondary | area under curve of steady state(AUCss) of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults. | up to 29 days | No | |
Secondary | Degree of fluctuation(DF) of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults. | up to 29 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |